CN115957190A

CN115957190A - Amifostine for injection and preparation method thereof

Info

Publication number: CN115957190A
Application number: CN202310027923.5A
Authority: CN
Inventors: 石磊; 王新房; 杨晓霞; 邢宝华; 刘可娜; 张银霞
Original assignee: Jiangsu Mingsheng Kangyuan Pharmaceutical Co ltd; KAIFENG MINGREN PHARMACEUTICAL CO Ltd
Current assignee: Jiangsu Mingsheng Kangyuan Pharmaceutical Co ltd; KAIFENG MINGREN PHARMACEUTICAL CO Ltd
Priority date: 2023-01-09
Filing date: 2023-01-09
Publication date: 2023-04-14

Abstract

The invention relates to an amifostine for injection and a preparation method thereof, comprising the following steps: s1, dissolving amifostine in water for injection, and stirring to obtain an amifostine injection solution; s2, adding a freeze-drying protective agent and an excipient into the amifostine injection solution obtained in the step S1, and adjusting the pH value to 6.5-7.5 to obtain a mixed solution; s3, heating the mixed solution obtained in the step S2 to 15-25 ℃ for constant temperature treatment to obtain a reaction product; s4, filtering the reaction product obtained in the step S3 by using a PES (polyether sulfone) membrane; and S5, filling the filtrate obtained in the step S4 into a freeze-drying tubular injection bottle, placing the freeze-drying tubular injection bottle on a plate layer of a freeze-dryer for freeze-drying, and pressing to obtain the amifostine for injection. The invention has the advantages that the quality index of the obtained product meets the new quality standard of the amifostine for injection, and the yield of the qualified product of the obtained product appearance is improved.

Description

Amifostine for injection and preparation method thereof

Technical Field

The invention relates to the technical field of medicines, in particular to amifostine for injection and a preparation method thereof.

Background

The chemical structural formula of the amifostine is H ₂ N-(CH ₂ ) ₃ -NH-(CH ₂ ) ₂ -SPO ₃ H ₂ Is an organic sulfurized phosphoric acid compound; it is hydrolyzed and dephosphorylated by alkaline phosphatase combined with cell membrane in tissue to obtain active metabolite WR-1065 with chemical structural formula of H ₂ N-(CH ₂ ) ₃ -NH-(CH ₂ ) ₂ The mercapto group has the function of eliminating free radicals in tissues, so that the toxicity of cisplatin, cyclophosphamide, mitomycin and the like can be reduced. The amifostine is a normal cell protective agent, is mainly used for the adjuvant therapy of various cancers, is applied before the chemotherapy is carried out on various cancer patients such as lung cancer, ovarian cancer, breast cancer, nasopharyngeal carcinoma, bone tumor, digestive tract tumor, blood system tumor and the like, can obviously reduce the toxicity of the kidney, bone marrow, heart, ear and nervous system generated by the chemotherapy medicament without reducing the efficacy of the chemotherapy medicament; the product can be applied before radiotherapy to significantly reduce xerostomia and mucositis.

The aqueous solution based on the amifostine is unstable, is greatly influenced by temperature change, and is easy to degrade in the placing process.

Disclosure of Invention

The invention aims to overcome the defects in the prior art and provide the amifostine for injection and the preparation method thereof, the quality index of the obtained product meets the new quality standard of the amifostine for injection, and the yield of the qualified product of the obtained product in appearance is improved.

The invention is realized by the following technical scheme: on the one hand, the preparation method of the amifostine for injection comprises the following steps:

s1, dissolving amifostine in water for injection, and stirring to obtain an amifostine injection solution;

s2, adding a freeze-drying protective agent into the amifostine injection solution obtained in the step S1, and adjusting the pH value to 6.5-7.5 to obtain a mixed solution;

s3, heating the mixed solution obtained in the step S2 to 15-25 ℃ for constant temperature treatment to obtain a reaction product;

s4, filtering the reaction product obtained in the step S3 by using a PES (polyether sulfone) membrane;

and S5, filling the filtrate obtained in the step S4 into a freeze-drying tube injection bottle, placing the freeze-drying tube injection bottle on a plate layer of a freeze-dryer for freeze-drying, and pressing a stopper to obtain the amifostine for injection.

The invention aims to provide a stable freeze-dried amifostine sterile preparation of amifostine, which is composed of amifostine crystals with uniformly arranged crystal grains and has stable performance. The invention also aims to provide an industrial production method for preparing the stable freeze-dried amifostine sterile freeze-dried preparation;

further, in step S1, the volume percentage of the amifostine to the water for injection is 1. Dissolving amifostine in 60-80% (v/v) of injection water, adding ethanol after dissolving, dissolving and uniformly mixing, and continuously adding the injection water to the total weight of the prescription amount to obtain ethanol and amifostine water solution.

Through the technical scheme, the stable aqueous solution of the amifostine and the ethanol is provided, which is beneficial to improving the efficiency of the freeze-drying process and the stability of the freeze-dried product

Further, in step S2, the lyoprotectant is ethanol or ethylene glycol.

By adopting the technical scheme, the crystallization speed and the crystal form uniformity of the amifostine crystal in the freeze-drying process can be improved by using ethanol or ethylene glycol

Further, in step S2, the ratio of the lyoprotectant is 10% to 21% (v/v) by volume percentage.

By the technical scheme, the stability of the solution is controllable under the condition of the proportion, and crystals appear under the liquid state

Further, in step S4, the PES membrane has a pore size of 0.2 μm.

In the scheme, after the liquid medicine is completely dissolved, the ethanol does not perform chemical reaction on the raw materials in the scheme, the raw materials are insoluble in the ethanol, the crystallization speed of the raw materials is better improved in the freeze-drying process, a PES (polyether sulfone) membrane with the aperture of 0.2 mu m is adopted to filter microorganisms in the liquid, the product quality in the product production is ensured, and the liquid medicine in an aseptic state is obtained.

Further, the solution amount of the freeze-dried controlled injection bottle is 6-10 mL/bottle.

Further, in step S5, the lyophilization process is as follows: after the partition board is boxed at the temperature of minus 5 ℃ for 1 to 2 hours, cooling the temperature to be below minus 40 ℃ for 1 hour, and keeping the temperature for 2 to 3 hours; the shelf is heated to-15 ℃ within 2 hours, and the temperature of the clapboard is maintained for 4-5 hours; the shelf is heated to-20 ℃ in 2 hours and is kept at the constant temperature for 3-4 hours; the shelf is heated from minus 20 ℃ to minus 10 ℃ in 1 hour, and the temperature is kept constant for 8 to 12 hours; the shelf is heated from-10 ℃ to-5 ℃ in 30 minutes and is kept at the constant temperature for 4-8 hours; the shelf is heated from minus 5 ℃ to 0 ℃ for 30 minutes and is kept at the constant temperature for 6 to 8 hours; the shelf is heated from 0 ℃ to 5 ℃ in 30 minutes and is kept at the constant temperature for 4-6 hours; the temperature of the shelf is increased from 5 ℃ to 10 ℃ in 30 minutes, when the temperature of the product is close to the temperature of the shelf, the temperature is kept for 3 to 6 hours, and the chamber is filled with nitrogen gas of 300 to 800Pa after the freeze drying is finished.

By the freeze-drying scheme, crystals are separated out from the liquid medicine in a solid state within the temperature range of-15 to-10, the crystals are gradually enlarged, fuller amifostine crystals are obtained, and water is sublimated in the process.

1. Further, in step S5, the amifostine for injection is a freeze-dried powder, and the crystals are uniform and loose; good re-solubility.

By adopting the technical scheme, the total impurities in the obtained amifostine for injection are less than or equal to 2.0 percent; the content of the amifostine reaches 97 percent, and the new quality standard of the amifostine for injection is met.

In addition, the preparation method of the amifostine for injection is used for preparing the amifostine for injection.

By adopting the technical scheme, the yield of the appearance qualified product of the obtained product reaches 90 percent.

The invention has the beneficial effects that: the quality index of the obtained product meets the quality standard of the amifostine for injection, and the yield of the appearance qualified product of the obtained product is improved. The product is white block-shaped, the crystal is arranged uniformly, loose and porous, the crystal is dissolved quickly and completely after being added with water, and the water solubility of the freeze-dried preparation is particularly good.

Detailed Description

The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.

Example 1

A preparation method of amifostine for injection comprises the following steps:

/>

s1, dissolving 5g of amifostine in 40g of water for injection, adding the water for injection to the total weight of 50g, and stirring to obtain an amifostine injection solution;

s2, adding 6g of ethanol into the amifostine injection solution obtained in the step S1, and adjusting the pH value to 7.0 to obtain a mixed solution;

s4, filtering the reaction product obtained in the step S3 by using a PES (polyether sulfone) membrane with the thickness of 0.2 mu m;

and S5, filling the filtrate obtained in the step S4 into a 10mL freeze-drying tube injection bottle, placing the freeze-drying tube injection bottle on a plate layer of a freeze-dryer for freeze-drying, and pressing to obtain the amifostine for injection.

Example 2

A preparation method of amifostine for injection comprises the following steps:

prescription components	Dosage of	Action
			Amifostine	5g	Active ingredient
Ethanol	8g	Freeze-drying protective agent
			Adding water for injection	50g	Solvent(s)

S1, dissolving 5g of amifostine in 40g of injection water, adding the injection water to the total weight of 50g, and stirring to obtain an amifostine injection solution;

s2, adding 8g of ethanol into the amifostine injection solution obtained in the step S1, and adjusting the pH value to 7.0 to obtain a mixed solution;

s4, filtering the reaction product obtained in the step S3 by using a PES (polyether sulfone) membrane with the diameter of 0.2 mu m;

and S5, filling the filtrate obtained in the step S4 into a penicillin bottle of 10mL, placing the penicillin bottle on a plate layer of a freeze dryer for freeze drying, and pressing a stopper to obtain the amifostine for injection.

Example 3

A preparation method of amifostine for injection comprises the following steps:

prescription components	Amount of the composition	Function of
			Amifostine	5g	Active ingredient
Ethanol	10g	Freeze-drying protective agent
			Adding water for injection	50g	Solvent(s)

s2, adding 10g of ethanol into the amifostine injection solution obtained in the step S1, and adjusting the pH value to 7.0 to obtain a mixed solution;

Example 4

A preparation method of amifostine for injection comprises the following steps:

prescription components	Dosage of	Function of
			Amifostine	5g	Active ingredient
Ethanol	12g	Freeze-drying protective agent
			Adding water for injection	50g	Solvent(s)

s2, adding 12g of ethanol into the amifostine injection solution obtained in the step S1, and adjusting the pH value to 7.0 to obtain a mixed solution;

and S5, filling the filtrate obtained in the step S4 into a 10mL penicillin bottle, placing the penicillin bottle on a plate layer of a freeze dryer for freeze drying, and pressing a stopper to obtain the amifostine for injection.

Example 5

A preparation method of amifostine for injection comprises the following steps:

prescription components	Amount of the composition	Action
			Amifostine	5g	Active ingredient
Ethanol	14g	Freeze-drying protective agent
			Adding water for injection	50g	Solvent(s)

s2, adding 14g of ethanol into the amifostine injection solution obtained in the step S1, and adjusting the pH value to 7.0 to obtain a mixed solution;

Please supplement examples showing other classes and ratios of lyoprotectants, excipients;

example 6

A preparation method of amifostine for injection comprises the following steps:

prescription components	Amount of the composition	Function of
			Amifostine	5g	Active ingredient
Ethylene glycol	14g	Freeze-drying protective agent
			Adding water for injection	50g	Solvent(s)

s2, adding 14g of ethylene glycol into the amifostine injection solution obtained in the step S1, and adjusting the pH value to 7.0 to obtain a mixed solution;

Comparative effect example

The results of the comparison of the amifostine products for injection from the above examples 1 to 6 are shown in the following table 1:

TABLE 1 Freeze-drying product test data

From the comparison results in table 1 above, it can be seen that when the temperature of the liquid medicine preparation is controlled to be 15-25 ℃, ethanol is added in different proportions in examples 1-5, and the relevant substances of the finished preparations of the examples have no significant difference, which indicates that the sample is equivalent in impurity level by the amount of ethanol added. In addition, under the same freeze-drying process conditions, the freeze-drying appearance is obviously improved by adding ethanol, each sample meets the requirements, the water content in different proportions is slightly different, the ethanol dosage proportion is large, the product water content is high, and the property appearance is not good when the dosage is small;

the results of the stability test of amifostine for injection example 1 are shown in table 2 below:

table 2.

The results of the stability test of amifostine for injection example 2 are shown in table 3 below:

table 3.

The results of the stability test of amifostine for injection example 3 are shown in table 4 below:

table 4.

Comparative example 1

A preparation method of amifostine for injection comprises the following steps:

prescription components	Dosage of	Function of
			Amifostine	5g	Active ingredient
Adding water for injection	50g	Solvent(s)

s2, heating the mixed solution obtained in the step S1 to 10 ℃ for constant temperature treatment to obtain a reaction product;

s3, filtering the reaction product obtained in the step S2 by using a PES (polyether sulfone) membrane with the diameter of 0.2 mu m;

and S4, filling the filtrate obtained in the step S3 into a penicillin bottle of 10mL, placing the penicillin bottle on a plate layer of a freeze dryer for freeze drying, and pressing a stopper to obtain the amifostine for injection.

Comparative example 2

A preparation method of amifostine for injection comprises the following steps:

s2, heating the mixed solution obtained in the step S1 to 15 ℃ for constant temperature treatment to obtain a reaction product;

and S4, filling the filtrate obtained in the step S3 into a 10mL penicillin bottle, placing the penicillin bottle on a plate layer of a freeze dryer for freeze drying, and pressing a stopper to obtain the amifostine for injection.

Comparative example 3

A preparation method of amifostine for injection comprises the following steps:

prescription components	Dosage of	Action
			Amifostine	5g	Active ingredient
Adding water for injection	50g	Solvent(s)

s2, heating the mixed solution obtained in the step S1 to 20 ℃ for constant temperature treatment to obtain a reaction product;

Comparative example 4

A preparation method of amifostine for injection comprises the following steps:

s2, heating the mixed solution obtained in the step S1 to 25 ℃ for constant temperature treatment to obtain a reaction product;

Comparative example of Effect

The results of comparing the amifostine products for injection in comparative examples 1 to 3 are shown in the following table 5:

TABLE 5 Freeze-drying product test data

Item	Temperature for preparing liquid medicine	Content of intermediate product	Freeze-drying appearance forming rate	Content (wt.)
					Comparative example 1	10℃	95.4mg/g	12％	97.9％
Comparative example 2	15℃	96.6mg/g	12％	98.6％
					Comparative example 3	20℃	95.6mg/g	11％	98.4％
Comparative example 4	25℃	96.8mg/g	10％	98.8％

As can be seen from the comparison results in Table 1, when the preparation temperature of the medicinal liquid is controlled to be 10-25 ℃, the content of the intermediate medicinal liquid is normal, and the content of the finished product is normal; in the dissolving process, the lower the temperature is, the longer the dissolving time is, and the dissolving temperature can be set to be 15-25 ℃; in addition, under the same freeze-drying process conditions, the intermediate liquid medicine is not added with other excipients, and the yield of freeze-dried appearance qualified products is low.

Finally, it should be noted that: although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that modifications may be made to the embodiments or portions thereof without departing from the spirit and scope of the invention.

Claims

1. The preparation method of the amifostine for injection is characterized by comprising the following steps:

s2, adding a freeze-drying protective agent and an excipient into the amifostine injection solution obtained in the step S1, and adjusting the pH value to 6.5-7.5 to obtain a mixed solution;

2. The method for preparing amifostine for injection according to claim 1, wherein in step S1, the volume percentage of the amifostine to the mixed solvent of water for injection and ethanol is 1. Dissolving amifostine in 60-80% (v/v) of injection water, adding ethanol after dissolving, dissolving and uniformly mixing, and continuously adding the injection water to the total weight of the prescription amount to obtain ethanol and amifostine water solution.

3. The method of claim 1, wherein in step S2, the lyoprotectant is ethanol, a protectant. The preparation method comprises the following steps: dissolving the amifostine with 60-80% (v/v) of injection water, adding ethanol for dissolving, and fixing the volume to the total weight of the prescription amount by using the injection water to ensure that the final concentration of the ethanol is 10-21% (v/v), thereby obtaining the aqueous solution of the ethanol and the amifostine.

4. The method for preparing amifostine for injection according to the claim 1, wherein in the step S2, the excipient is ethanol.

5. The method for preparing amifostine for injection according to claim 1, wherein in step S2, the ratio of the lyoprotectant is 10-21% (v/v) by volume percentage.

6. The method for preparing amifostine for injection according to claim 1, wherein in step S4, the pore size of the PES membrane is 0.2 μm.

7. The method for preparing amifostine for injection according to claim 1, wherein the solution amount of the freeze-dried controlled injection bottle is 6-10 mL/bottle.

8. The method for preparing amifostine for injection according to the claim 1, wherein in the step S5, the freeze-drying process comprises the following steps: after the partition board is boxed at the temperature of minus 5 ℃ for 1 to 2 hours, cooling the temperature to be below minus 40 ℃ for 1 hour, and keeping the temperature for 2 to 3 hours; the shelf is heated to-15 ℃ within 2 hours, and the temperature of the clapboard is maintained for 4-5 hours; raising the temperature of the shelf to-20 ℃ in 2 hours, and keeping the temperature for 3-4 hours; the shelf is heated from minus 20 ℃ to minus 10 ℃ for 1 hour, and the temperature is kept for 8 to 12 hours; the shelf is heated from minus 10 ℃ to minus 5 ℃ in 30 minutes and is kept at the constant temperature for 4 to 8 hours; the shelf is heated from minus 5 ℃ to 0 ℃ for 30 minutes and is kept at the constant temperature for 6 to 8 hours; the shelf is heated from 0 ℃ to 5 ℃ in 30 minutes and is kept at the constant temperature for 4-6 hours; the temperature of the shelf board is increased from 5 ℃ to 10 ℃ in 30 minutes, when the temperature of the product is close to the temperature of the shelf board, the temperature is maintained for 3-6 hours, and after the freeze drying is finished, nitrogen gas is filled into the cavity at 300-800 Pa.

9. The method for preparing amifostine for injection according to claim 1, wherein in the step S5, the amifostine for injection is lyophilized powder. The character is white block, and the crystal is uniform and loose; after the freeze-drying is finished, nitrogen is filled into the box body to protect the product, and the box body is plugged, taken out of the box and covered by a rolling cover after the nitrogen is filled.

10. An amifostine for injection prepared by the method for preparing the amifostine for injection as claimed in any one of claims 1 to 9.